A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2011
10/13/2011	WO2011126352A2 Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof
10/13/2011	WO2011126071A1 Agent for inhibiting viral infection and/or treating infectious disease, and method for inhibiting viral infection and/or treating infectious disease
10/13/2011	WO2011125967A1 Cephem compound having catechol group
10/13/2011	WO2011125966A1 Cephem compound having pseudo-catechol group
10/13/2011	WO2011125600A1 Method and device for cell activation
10/13/2011	WO2011125469A1 Micro-rna-regulated recombinant vaccinia virus and utilization thereof
10/13/2011	WO2011124697A1 Antimicrobial compounds of 1,4- naphtoquinone structure
10/13/2011	WO2011124366A1 Piroxicam for prophylactically and therapeutically treating herpes infections
10/13/2011	WO2011124249A1 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts
10/13/2011	WO2011124093A1 Bicyclic quinolone compounds, preparation methods and uses thereof
10/13/2011	WO2011124056A1 Genetically engineered vaccine against lymphocystis disease in paralichthys olivaceus and method for producing the same
10/13/2011	WO2011123945A1 Compostions, methods and uses for treating respiratory syncytial virus infection
10/13/2011	WO2011123942A1 Fatty acid derivatives of catechins and methods of their use
10/13/2011	WO2011123900A1 Methods and compositions for inhibiting hiv transmission
10/13/2011	WO2011075806A3 Lentivirus vaccine based on the recombinant viral vaccine against yellow fever
10/13/2011	WO2011071981A3 Anti-cytomegalovirus activity of artemisinin-derived dimers
10/13/2011	WO2011067236A3 Raltegravir polymorphs
10/13/2011	WO2011063419A3 Lipopeptide compositions and related methods
10/13/2011	WO2011060408A3 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
10/13/2011	WO2011046996A3 Consensus sequence for influenza a virus
10/13/2011	WO2011037411A3 Composition comprising s-allyl-l-cysteine as active ingredient for preventing or treating gastrointestinal disorders
10/13/2011	WO2010132765A9 Antibacterial aminoglycoside analogs
10/13/2011	US20110251284 Halo active aromatic sulfonamide organic compounds and uses therefor
10/13/2011	US20110251264 Transcription factor decoys
10/13/2011	US20110251262 Compositions And Methods For Inhibiting Expression Of An RNA From West Nile Virus
10/13/2011	US20110251261 Compositions and methods for inhibition of nucleic acids function
10/13/2011	US20110251259 Compositions and methods for inhibiting expression of cd274/pd-l1 gene
10/13/2011	US20110251253 Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
10/13/2011	US20110251251 Polymorph ii of an antifungal compound
10/13/2011	US20110251231 Modified release compositions comprising tacrolimus
10/13/2011	US20110251226 Cyclohexylamin isoquinolone derivatives
10/13/2011	US20110251222 Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine
10/13/2011	US20110251210 Modified chloroquines with single ring moiety or fused ring moiety
10/13/2011	US20110251200 Aryl guanidine f1f0-atpase inhibitors and related methods
10/13/2011	US20110251193 1,2-benzisothiazolinone and isoindolinone derivatives
10/13/2011	US20110251192 Amide compounds, their pharmaceutical compositions, their preparation method and their uses
10/13/2011	US20110251179 3,4-DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES
10/13/2011	US20110251176 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
10/13/2011	US20110251168 3-aminopyrrolidine derivatives as modulators of chemokine receptors
10/13/2011	US20110251152 Nucleoside phosphoramidates
10/13/2011	US20110251148 Glycomimetic compounds and methods to inhibit infection by hiv
10/13/2011	US20110251147 Compositions Comprising Quinolone and Methods for Treating or Controlling Infections
10/13/2011	US20110251146 Topical antifungal composition
10/13/2011	US20110251144 Molecular modulators of the wnt/beta-catenin pathway
10/13/2011	US20110251141 Composition for topical treatment of mixed vaginal infections
10/13/2011	US20110251120 Antimicrobial Peptides and Methods of Identifying the Same
10/13/2011	US20110250693 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
10/13/2011	US20110250650 Lentiviral vectors for the preparation of immunotherapeutical compositions
10/13/2011	US20110250303 Feed for preventing and/or treating diseases caused by clostridium bacterium in livestock, and agent against clostridium
10/13/2011	US20110250287 One step removal of selected molecules from body fluid and tissue
10/13/2011	US20110250267 Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
10/13/2011	US20110250254 Antimicrobial compositions and uses
10/13/2011	US20110250243 Nanoparticle compositions
10/13/2011	US20110250240 Immune enhancing compositions and methods of use thereof
10/13/2011	US20110250237 Immunogenic amphipathic peptide compositions
10/13/2011	US20110250235 Production of a saccharide composition comprising glucans and mannans by alkaline and acid hydrolysis of yeast cells
10/13/2011	US20110250232 DNA-Transfection System for the Generation of Infectious Influenza Virus
10/13/2011	US20110250231 Method of using punicic acid to enhance immune response and prevent metabolic disorders
10/13/2011	US20110250227 Composition for treatment of the skin
10/13/2011	US20110250225 Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
10/13/2011	US20110250224 Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines
10/13/2011	US20110250223 Hybrid and tandem expression of neisserial proteins
10/13/2011	US20110250222 Antigenic polypeptides of chlamydia-related bacteria for diagnosis and vaccine
10/13/2011	US20110250221 Group A Streptococcus Pharmaceutical Compositions and Methods Thereof
10/13/2011	US20110250220 Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
10/13/2011	US20110250215 Structurally-related relaxin-fusion proteins with extended in vivo half-lives
10/13/2011	US20110250202 Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
10/13/2011	US20110250177 Alpha interferon variants
10/13/2011	US20110250176 Combinations of Hepatitis C Virus Inhibitors
10/13/2011	US20110250175 Tlr7 ligand and uses thereof
10/13/2011	US20110250173 Methods and compositions for inhibition of Treg cells
10/13/2011	US20110250172 Hepatitis c virus inhibitors
10/13/2011	US20110250168 Sialoadhesin-related compositions and methods
10/13/2011	US20110250167 Method for purifying proteins
10/13/2011	US20110250165 Antibodies against CXCR4 and Methods of Use Thereof
10/13/2011	US20110250153 Oligomeric biosurfactants in dermatocosmetic compositions
10/13/2011	US20110250151 Cold process water soluble wax containing powders
10/13/2011	US20110250134 Sustained release nitric oxide from long lived circulating nanoparticles
10/13/2011	US20110250130 Tnf-alpha binding proteins
10/13/2011	DE102010014290A1 Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen Means for prophylactic and therapeutic treatment of herpes infections
10/13/2011	CA2795853A1 Methods and compositions for inhibiting hiv transmission
10/13/2011	CA2795695A1 Microrna-controlled recombinant vaccinia virus and use thereof
10/13/2011	CA2795350A1 Ire-1.alpha. inhibitors
10/13/2011	CA2795334A1 Agent for prophylactic and therapeutic treatment of herpes infections
10/13/2011	CA2795322A1 Cephem compound having catechol group
10/13/2011	CA2795264A1 Glycomimetic compounds and methods to inhibit infection by hiv
10/13/2011	CA2794252A1 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts
10/13/2011	CA2794096A1 Methods for treating respiratory viral infection
10/13/2011	CA2791253A1 Polyol modified aminoglycoside-lipid conjugates
10/12/2011	EP2374894A2 A method for producing influenza hemagglutinin multivalent vaccines
10/12/2011	EP2374880A1 Method for inhibiting proliferation of cells
10/12/2011	EP2374806A1 OXAZOLIDINON-QUINOLONe HYBRIDes and intermediates for their preparation
10/12/2011	EP2374474A1 Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
10/12/2011	EP2374461A1 Piroxicam for prophylactic and therapeutic treatment of herpes infections
10/12/2011	EP2374453A1 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
10/12/2011	EP2373791A1 Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
10/12/2011	EP2373693A1 Compositions and methods for the treatment or the prevention oral infections by e. coli
10/12/2011	EP2373671A1 Uracyl cyclopropyl nucleotides
10/12/2011	EP2373645A1 Isoindolinone and related analogs as sirtuin modulators
10/12/2011	EP2373631A2 Antibacterial compounds

1 ... 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 ... 1798